We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.84%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.85B
AUM Growth
+$135M
Cap. Flow
-$725M
Cap. Flow %
-39.12%
Top 10 Hldgs %
58.55%
Holding
374
New
79
Increased
68
Reduced
92
Closed
116

Top Buys

Rank Stock Value
1
BIOA
BioAmber Inc.
BIOA
+$5.55M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.2M
3
OTIC
Otonomy, Inc.
OTIC
+$3.92M
4
BLRX
BioLineRX
BLRX
+$3.37M
5
SLS icon
SELLAS Life Sciences
SLS
+$2.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$62.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$59.7M
3
AMGN icon
Amgen
AMGN
+$35.8M
4
LLY icon
Eli Lilly
LLY
+$15.7M
5
BIIB icon
Biogen
BIIB
+$5.67M

Sector Composition

Rank Sector Weight
1 Healthcare 6.29%
2 Materials 0.25%
3 Financials 0.16%
4 Consumer Staples 0.04%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOCL
276
EDAP TMS S.A.
FOCL
$234M
– –
-22,993
Closed -$69.3K
FOLD
277
DELISTED
Amicus Therapeutics
FOLD
– –
-60,309
Closed -$381K
HALO icon
278
PUT
Halozyme
HALO
$9.88B
– –
-532
Closed -$526K
HCA icon
279
PUT
HCA Healthcare
HCA
$88.4B
– –
-100
Closed -$740K
HRTX icon
280
CALL
Heron Therapeutics
HRTX
$93.4M
– –
-141
Closed -$185K
HUM icon
281
CALL
Humana
HUM
$43.9B
– –
-291
Closed -$5.94M
IMNN icon
282
Imunon
IMNN
$6.47M
– –
-487
Closed -$416K
INSM icon
283
Insmed
INSM
$22.4B
– –
-48,043
Closed -$741K
IOVA icon
284
PUT
Iovance Biotherapeutics
IOVA
$2.04B
– –
-1,260
Closed -$876K
KPRX icon
285
Kiora Pharmaceuticals
KPRX
$11.4M
– –
-36
Closed -$314K
LLY icon
286
CALL
Eli Lilly
LLY
$1.08T
– –
-23,675
Closed -$174M
LLY icon
287
Eli Lilly
LLY
$1.08T
– –
-213,113
Closed -$15.7M
LLY icon
288
PUT
Eli Lilly
LLY
$1.08T
– –
-4,043
Closed -$29.7M
NBIX icon
289
CALL
Neurocrine Biosciences
NBIX
$18.2B
– –
-1,153
Closed -$4.46M
NKTR icon
290
CALL
Nektar Therapeutics
NKTR
$2.39B
– –
-7
Closed -$135K
NVAX icon
291
CALL
Novavax
NVAX
$1.21B
– –
-8
Closed -$20K
OPK icon
292
CALL
Opko Health
OPK
$1.02B
– –
-1,491
Closed -$1.39M
OPK icon
293
Opko Health
OPK
$1.02B
– –
-190,955
Closed -$1.61M
PBYI icon
294
CALL
Puma Biotechnology
PBYI
$398M
– –
-2,177
Closed -$6.68M
PCRX icon
295
CALL
Pacira BioSciences
PCRX
$1.04B
– –
-700
Closed -$2.26M
PCRX icon
296
PUT
Pacira BioSciences
PCRX
$1.04B
– –
-159
Closed -$514K
PHIO icon
297
Phio Pharmaceuticals
PHIO
$11.4M
– –
-7
Closed -$284K
PRQR icon
298
ProQR Therapeutics
PRQR
$244M
– –
-40,000
Closed -$196K
QNRX
299
Quoin Pharmaceuticals
QNRX
$8.6M
– –
-1
Closed -$177K
RCKT icon
300
CALL
Rocket Pharmaceuticals
RCKT
$343M
– –
-27
Closed -$65K
10 11
12
13 14

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sabby Management held 374 positions worth $1.85B, up 7.8% from $1.72B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management withdrew a net $725M in Q1 2017, closing 116 positions and reducing 92 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $62.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.3% of assets, down from 18% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in BioAmber Inc. worth $3.39M.

  • Sabby Management's largest Q1 2017 buy was BioAmber Inc.: 1,460,859 shares worth $3.39M.
  • Sabby Management added most to Otonomy, Inc. in Q1 2017, an estimated $3.92M increase.
  • Sabby Management's biggest Q1 2017 reduction was Amgen, cutting an estimated $35.8M.
  • Sabby Management fully exited Sarepta Therapeutics in Q1 2017, selling an estimated $62.4M.
  • Sabby Management's ten largest holdings make up 59% of its $1.85B portfolio in Q1 2017.
  • Sabby Management opened 79 new positions and closed 116 in Q1 2017.
  • Sabby Management's portfolio value rose 7.8% quarter-over-quarter to $1.85B.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.